Neubond develops a forearm-worn wristband and companion app that detect faint muscle electrical signals and deliver sensory biofeedback to help rebuild neural connections after stroke. The platform was developed from over a decade of research in Imperial College London’s Neuromechanics and Rehabilitation Technology lab and was founded by Dr Patrick Sagastegui Alva and Jumpei Kashiwakura with Professor Dario Farina as a co-founder. In a 15-patient pilot, users experienced a 30% increase in range of motion after one month, and the company is running a clinical feasibility study at Charing Cross Hospital to prepare for a randomized controlled trial. Neubond raised £1.5 million in seed funding to finalise the device, pursue MHRA certification, and support its clinical programme. The company is positioning its regulatory and commercial approach toward NHS adoption and exploring broader applications of its neural interface in areas like exoskeleton control.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026